title stringlengths 1 1.19k | keywords stringlengths 0 668 | concept stringlengths 0 909 | paragraph stringlengths 0 61.8k | PMID stringlengths 10 11 |
|---|---|---|---|---|
Assessments | RTT | SECONDARY | Coprimary and key secondary efficacy assessments using the RSBQ, the CGI-I scale and the CSBS-DP-IT Social Composite score were completed at baseline (except the CGI-I scale) and at each visit (weeks 2, 6 and 12 (or end of treatment)). The RSBQ is a caregiver-completed scale assessing key symptoms of RTT | PMC10287558 |
Efficacy endpoints | SECONDARY | Coprimary endpoints were the change from baseline to week 12 in RSBQ total score and the CGI-I scale score at week 12. The key secondary endpoint was the change from baseline to week 12 in the CSBS-DP-IT Social Composite score. A prespecified subgroup analysis examined treatment effects by age, baseline RSBQ severity a... | PMC10287558 | |
Post hoc efficacy analyses | TEAE, diarrhea | Two additional efficacy analyses were conducted post hoc: CGI-I scale responders (scores ≤3) at week 12 and coprimary endpoints assessed in the presence or absence of the most commonly reported TEAE of diarrhea. | PMC10287558 | |
Statistical analysis | SECONDARY | A sample size of 184 participants (92 per group) was planned to provide 90% power for both coprimary endpoints combined with a two-sided significance level of 0.05. Efficacy was assessed in the full analysis set (received at least one dose and had a baseline value and at least one post-baseline value for the RSBQ or th... | PMC10287558 | |
Reporting summary | Further information on research design is available in the | PMC10287558 | ||
Online content | Any methods, additional references, Nature Portfolio reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at 10.1038/s41591-023-02398-1. | PMC10287558 | ||
Supplementary information |
Supplementary Tables 1 and 2.Reporting SummaryFinal version of the statistical analysis plan.Final version of the study protocol. | PMC10287558 | ||
Source data |
Clinical study report.Clinical study report.Clinical study report.Clinical study report.Clinical study report.Clinical study report.Clinical study report.Clinical study report.Clinical study report. | PMC10287558 | ||
Extended data | PMC10287558 | |||
Alanine Aminotransferase Values. | Figure footnote: The dashed vertical line at day 1 indicates when study treatment was initiated.
| PMC10287558 | ||
Extended data | is available for this paper at 10.1038/s41591-023-02398-1. | PMC10287558 | ||
Supplementary information | The online version contains supplementary material available at 10.1038/s41591-023-02398-1. | PMC10287558 | ||
Acknowledgements | P., UC | HAAS | We thank the trial participants, their families and our fellow investigators involved in this trial: B. Suter (Texas Children’s Hospital, Houston, Texas, US), C. Buhrfiend, P. Heydemann (Rush University Children’s Hospital, Chicago, Illinois, US), S. Standridge, E. Broomall, K. Peariso (Cincinnati Children’s Hospital M... | PMC10287558 |
Author contributions | The sponsor, Acadia Pharmaceuticals, and J.L.N., A.K.P., T.A.B., E.M.B.-K. and D.G.G. conceived and designed the study; all authors conducted the study and collected data, performed the formal analysis, participated in data interpretation, critically revised the manuscript content for important intellectual content, ap... | PMC10287558 | ||
Peer review | PMC10287558 | |||
Data availability | This clinical trial was sponsored by Acadia Pharmaceuticals. Acadia supports data sharing consistent with the Principles for Responsible Clinical Trial Data Sharing and International Committee of Medical Journal Editors’ recommendations. Acadia shares data from completed clinical trials through public registries ( | PMC10287558 | ||
Competing interests | Rett Syndrome | RETT SYNDROME | J.L.N. has received research funding from the International Rett Syndrome Foundation, the National Institutes of Health and Rett Syndrome Research Trust; and personal consultancy fees from Acadia Pharmaceuticals, Analysis Group, AveXis, GW Pharmaceuticals, Hoffmann-La Roche, Myrtelle, Neurogene, Newron Pharmaceuticals,... | PMC10287558 |
References | PMC10287558 | |||
1. Introduction | gastrointestinal symptoms, lactose intolerance [Gastric transit, abdominal pain | Lactose maldigesters report an increase in abdominal pain due to the consumption of milk containing a mixture of A1 and A2 β-casein as compared to milk containing only A2 β-casein. Gastric transit affects gastrointestinal symptoms and rapid transit has been associated with an increase in abdominal pain. We conducted a ... | PMC9963893 | |
2. Materials and Methods | PMC9963893 | |||
2.1. Subject Enrolment, Allocation and Inclusion Criteria | RECRUITMENT | This was a randomized, double-blinded, crossover trial. Subjects aged 18–65 years were recruited using flyers, advertisements in local and campus newspapers and email. The recruitment started in March 2021 and the data collection was completed in October 2022. Sixty-one people indicated an interest in the study and con... | PMC9963893 | |
2.2. Exclusion Criteria | HIV, hepatitis B, diabetes mellitus, ulcers, gastrointestinal tract | ADVERSE EVENTS, DIABETES MELLITUS, ULCERS, CONGESTIVE HEART FAILURE, HEPATITIS C, ABNORMAL GASTROINTESTINAL MOTILITY | Subjects were excluded from the study if they met one or more of the following criteria: currently pregnant, abnormal gastrointestinal motility, history of gastrointestinal tract surgery, presence of a medical condition that could confound collection of adverse events, ulcers, diabetes mellitus, congestive heart failur... | PMC9963893 |
2.3. Intervention | Two milks were fed: Conventional milk containing 75% A1 β-casein and 25% A2 β-casein (Kroger | PMC9963893 | ||
2.4. Nutrient Analysis | Total sugar, fat and protein in conventional milk and A2 milk were analyzed by Eurofins Food Integrity and Innovation (Eurofins Food Chemistry Testing US, Inc., Madison WI, USA). A1 and A2 β-casein in the two types of milk were analyzed using mass spectrometry at Purdue Proteomics Facility. | PMC9963893 | ||
2.4.1. Analysis of A1 β-Casein/A2 β-Casein Using Liquid Chromatograph Triple Quadrupole Mass Spectrometer (LC-MS/MS) | SEPARATION, AIDS | One hundred microliters (100 µL) of each milk sample (conventional milk and A2 milk) were denatured using 400 µL of 8 M urea and 10 mM DTT (dithiotheitol), and vortexed for 15 min at room temperature. Denaturation with urea aids in the separation of fat from protein. Fat removal was followed by the process of centrifug... | PMC9963893 | |
2.4.2. Sugar Analysis | The analysis for the sugar profile was conducted using gas chromatography with flame ionization detection [ | PMC9963893 | ||
2.4.3. Protein Analysis | Dumas method, also known as combustion method, was used to analyze protein in milk samples [ | PMC9963893 | ||
2.4.4. Fat Analysis | Base hydrolysis was the method used to determine the fat content in milk samples [ | PMC9963893 | ||
2.5. Study Procedure | abdominal pain | Subjects reported to Purdue MRI Facility for two visits, at least six days apart. Subjects consumed a low-fiber dinner the night before the test feeding, fasted twelve hours prior to their visit and avoided drinking water three hours prior to the visit. On the day of the visit, scans were performed using a Magnetom 3T ... | PMC9963893 | |
2.6. Study Ethics | The study protocol (ClinicalTrials.gov #NCT05658861) was reviewed and approved by the Purdue University Institutional Review Board (#IRB-2019-296). The study complied with the Helsinki Declaration of 1975 as revised in 2008 [ | PMC9963893 | ||
2.7. Image Analysis | A software tool within FMRIB’s Software Library (FSL v5.0.11) [ | PMC9963893 | ||
2.8. Statistical Analysis | USA).The, USA).Conventional milk, abdominal pain | The volume of both kinds of milk in the stomach during the two-hour study was compared using two-way repeated measures ANOVA. The normality of the data was tested using Shapiro–Wilk. Log transformation was used to bring the data into a normal distribution. This analysis was conducted using RStudio (v2022.07.2+576.pro12... | PMC9963893 | |
3. Results | PMC9963893 | |||
3.1. Baseline Characteristics | maldigestion | Five out of the twenty-three subjects who were phone screened were ineligible to continue in the study due to their current medical condition, lack of milk avoidance and/or presence of metallic implants near the region of the scan. The remaining eighteen were eligible to be assessed for maldigestion with a hydrogen bre... | PMC9963893 | |
3.2. Nutrient Analysis | The nutrient compositions of the A2 milk and conventional milk are shown in | PMC9963893 | ||
3.3. Gastric Emptying and Transit Volume | The average volume of conventional milk in the stomach over the two-hour period was significantly lower than the average volume of A2 milk ( | PMC9963893 | ||
3.4. Abdominal Pain | abdominal pain | The total symptom score for abdominal pain reported by all maldigesters was 20 for conventional milk and 12 for A2 milk. This difference was not statistically significant ( | PMC9963893 | |
3.5. Adverse Events | ADVERSE EVENTS | There were no adverse events reported by subjects during the study. | PMC9963893 | |
4. Discussion | milk, New-World milk, lactose intolerance, gastrointestinal and colonic transit | LACTOSE INTOLERANCE | No previously reported studies have compared the gastric emptying time of milk containing A1 and A2 β-casein with milk containing only A2 β-casein. Therefore, this pilot study could be used for power calculations for larger-scale studies. We planned to recruit 10 subjects to examine a difference in transit. We complete... | PMC9963893 |
5. Conclusions | maldigestion, abdominal pain | In summary, the gastric transit of milk containing both A1 and A2 β-casein was faster as compared to milk containing only A2 β-casein. The abdominal pain resulting from New-World milk and A2 milk was not different, likely due to the small sample size. The transit findings reported here could be the reason for less mald... | PMC9963893 | |
Author Contributions | Conceptualization, D.A.S. and M.R.; methodology, M.R., X.Z., U.D. and D.A.S.; formal analysis, M.R. and X.Z.; writing—original draft preparation, M.R.; writing—review and editing, M.R. and D.A.S. All authors have read and agreed to the published version of the manuscript. | PMC9963893 | ||
Institutional Review Board Statement | The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of Purdue University (protocol IRB-2019-296 approved on 02 September 2021). | PMC9963893 | ||
Informed Consent Statement | Informed consent was obtained from all subjects involved in the study. | PMC9963893 | ||
Data Availability Statement | The data presented in this study are available on request from the corresponding author. The data are not publicly available due to privacy and ethical restrictions. | PMC9963893 | ||
Conflicts of Interest | The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. | PMC9963893 | ||
Appendix A | PMC9963893 | |||
Inclusion and Exclusion Criteria for Phone Screening | mellitus, IBS, Crohn’s disease, UC, amyloidosis, abnormal gastrointestinal motility, chronic constipation, aneurysm, uremia, gastrointestinal bypass, alcoholism, ulcerative colitis, SIBO, diverticulosis, epilepsy/seizure, prostate radiation, gastroparesis, Hepatitis, Hepatitis B, cardiac defibrillator, IBD, GERD, Parki... | INFLAMMATORY BOWEL DISEASE, GERD, ULCERS, AMYLOIDOSIS, NEUROMUSCULAR DISEASES, CELIAC DISEASE, ANEURYSM, UREMIA, GASTRO-ESOPHAGEAL REFLUX DISEASE, DISORDERS, BILIARY DISEASE, CHRONIC PANCREATITIS, ABNORMAL GASTROINTESTINAL MOTILITY, CONGESTIVE HEART FAILURE, ULCERATIVE COLITIS, BACTERIAL OVERGROWTH SYNDROME, DIVERTICUL... | Inclusion Criteria:Ability/desire to provide informed consentAged 18 to 65 years inclusive at screeningMilk intolerant and identified as a lactose maldigester while participating in the Milk Protein Study (applicable only for subjects from the previous milk protein study and not applicable for new subjects)Current or r... | PMC9963893 |
References | abdominal pain | Study flow. HBT, hydrogen breath test; MRI, magnetic resonance imaging analysis.Image analysis using FMRIB’s Software Library (FSL v5.0.11). (Image analysis using FMRIB’s Software Library (FSL v5.0.11). (The volume of A2 milk in the stomach was significantly lower at 30, 60 and 120 min as compared to the volume of conv... | PMC9963893 | |
Objective | ORAL MUCOSITIS, ACUTE LEUKEMIA | This study aimed to investigate the clinical effects of recombinant human interleukin-11 (rhIL-11) gargle on preventing and treating oral mucositis (OM) after chemotherapy for acute leukemia. | PMC10337102 | |
Methods | mucositis, pain | MUCOSITIS, ORAL MUCOSITIS, ACUTE LEUKEMIA | This single-site, prospective, observer-blinded, nonrandomized controlled trial was conducted on 74 patients with acute leukemia, who were divided into the experimental and control groups. The patients in the experimental group were treated with IL-11 gargle, and those in the control group were treated with sodium bica... | PMC10337102 |
Results | pain, ulcer, Mucositis | ULCER, MUCOSITIS | The proportion of patients with severe OM was significantly lower in the experimental group than in the control group. Mucositis occurred later in the experimental group compared with the control group. The degree and duration of pain, ulcer healing time, and effects on eating were lower in the experimental group compa... | PMC10337102 |
Conclusions | pain | ACUTE LEUKEMIA | IL-11 gargle reduced the severity of OM after chemotherapy for acute leukemia. Treatment with IL-11 relieved pain, promoted healing, and improved the curative effect of the condition, making it worthy of clinical promotion. | PMC10337102 |
Keywords | PMC10337102 | |||
Introduction | cancer of the hematopoietic system, leukemia, erythema, ulcers, malignant tumors, systemic infection, acute leukemia | ORAL MUCOSITIS, LEUKEMIA, DISEASE, ERYTHEMA, ULCERS, COMPLICATION, MALIGNANT TUMORS, SYSTEMIC INFECTION, BONE MARROW SUPPRESSION, ACUTE LEUKEMIA, ACUTE LEUKEMIA | Oral mucositis (OM) is an inflammatory reaction of epithelial tissue that involves symptoms such as oral mucosal erythema and ulcers. The main antitumor treatments that cause OM include chemotherapy, radiotherapy, molecular targeted therapy, and hematopoietic stem cell transplantation for malignant tumors [Acute leukem... | PMC10337102 |
Patients and methods | PMC10337102 | |||
Patients | PMC10337102 | |||
Patient demographics | AML, acute leukemia | ACUTE MYELOID LEUKEMIA, ADULT AML, AML, SECONDARY, ACUTE LEUKEMIA | This study involved 74 patients with acute leukemia (including secondary and transformed) admitted to our hospital from June 2021 to June 2022. This group consisted of 59 patients with acute myeloid leukemia (AML), who all met the diagnostic criteria for adult AML from the Chinese Medical Association [ | PMC10337102 |
Inclusion criteria | AML, ALL | AML, ACUTE LEUKEMIA | Patients were included in this study if they (1) had AML or ALL diagnosed by bone marrow aspiration and flow immunophenotyping and receiving the first course of induction chemotherapy; (2) were diagnosed with acute leukemia, after complete response (CR), and receiving a course of consolidation and intensive chemotherap... | PMC10337102 |
Exclusion criteria | ORAL ULCERS, PERIODONTAL DISEASES, MALIGNANT TUMORS, OTHER INFECTIOUS DISEASES, DISEASES | Patients were excluded from this study if they (1) had active periodontal diseases that required treatment and refractory oral ulcers prior to this study; (2) were pregnant and lactating; (3) presented with other malignant tumors; (4) had other infectious diseases; or (5) had severe heart, brain, lung, liver, kidney, o... | PMC10337102 | |
Methods | PMC10337102 | |||
Chemotherapy regimens | ALL | AML | Each patient in this study was treated with a reasonable chemotherapy regimen based on their own conditions. Drugs commonly used to treat AML include idarubicin, cytarabine, high-spinel, etoposide, fludarabine, cladribine, azacitidine, decitabine, arsenic acid, venetoclax, and other novel chemotherapy drugs. Drugs comm... | PMC10337102 |
OM treatment | bone marrow suppression | MUCOSAL ULCERS, REMISSION, DETACHMENT, BONE MARROW SUPPRESSION | As part of the intervention, the patients in the experimental group gargled with IL-11 rinse, which was formulated as follows: 3 mg of IL-11 was added to 100 mL of normal saline, which was then stored at 2–8 °C and dispensed every day. The patients in the control group gargled with a solution of 5% sodium bicarbonate a... | PMC10337102 |
Observation indicators | agranulocytosis, erosion, pain | DISEASE, EROSION, DISEASES, GRANULOCYTOSIS | The main observation indicators used in this study were as follows: (1) the severity of OM and its timing relative to the first day of chemotherapy; (2) the severity of the pain caused by OM and the duration from the onset of pain to its relief; (3) the time from the inception of OM to its healing; (4) the influence of... | PMC10337102 |
Statistical analysis | SPSS 20.0 software was used to perform all statistical analyses. The continuous data were expressed as mean ± standard deviation (x ± s) and compared using the | PMC10337102 | ||
Results | PMC10337102 | |||
Patient characteristics | The 74 patients were divided between the experimental and control groups, with 37 patients in each group. Patient inclusion, exclusion, and follow-up are shown in Fig.
Patients inclusion, exclusion, and follow-up
Comparison of baseline clinical data between the observation and control groups | PMC10337102 | ||
Severity and timing of OM | More patients in the experimental group had OM of grade 0 and grade I, whereas more patients in the control group had OM of grade II and above (
OM stage and timing after chemotherapy | PMC10337102 | ||
Level and duration of OM pain | pain | The patients in the experimental group mostly experienced painlessness or mild symptoms of pain, whereas the patients in the control group had significantly higher levels of moderate and severe pain (
Level and duration of OM pain | PMC10337102 | |
Effects of OM on eating and mucosal healing time | The onset of OM had a significantly higher impact on eating in the control group compared with the experimental group (
OM effects on eating and healing time | PMC10337102 | ||
T-cell subset detection before and after treatment | Prior to treatment, the CD3+, CD4+, CD8+, and CD4+/CD8 + levels did not significantly differ between the two groups. The levels of each of these indicators increased as a result of IL-11 treatment, where the rate of increase in the experimental group was significantly higher than that in the control group (
T-cell subs... | PMC10337102 | ||
Discussion | pulpitis, swelling, inflammation, edema, periodontitis, infections, pain, infection, active periodontal diseases, friction, mucositis, ALL, Acute leukemia, acute leukemia | PERIODONTAL DISEASE, PULPITIS, ACUTE LEUKEMIA, PERIAPICAL PERIODONTITIS, INFLAMMATORY RESPONSES, INFLAMMATION, EDEMA, INFECTIONS, REMISSION, MUCOSITIS, DISEASES, ACUTE LEUKEMIA, PERIODONTITIS, INFECTION, COMPLICATIONS, INFILTRATE, DISEASE, MALNUTRITION, MUCOSAL INFLAMMATION | Acute leukemia is a malignant clonal disease involving hematopoietic stem cells. Abnormal primitive cells proliferate and extensively infiltrate the bone marrow to inhibit normal hematopoiesis. At present, combined chemotherapy remains the primary form of treatment for acute leukemia. Acute leukemia commonly causes OM ... | PMC10337102 |
Acknowledgements | None. | PMC10337102 | ||
Authors’ contributions | YL Z, YX L and XR M carried out the studies, participated in collecting data, and drafted the manuscript. J W, PY Z, AL H and B L performed the statistical analysis and participated in its design. Z H, L Z and W Z participated in acquisition, analysis, or interpretation of data and draft the manuscript. All authors rea... | PMC10337102 | ||
Funding | None. | PMC10337102 | ||
Data availability | All data generated or analysed during this study are included in this published article. | PMC10337102 | ||
Declarations | PMC10337102 | |||
Ethics approval and consent to participate | All procedures were performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. This study was approved by the Ethics Committee of the Second Affiliated Hospital of Xi’an Jiaotong University. All patients provided written informed consent prior to treatment... | PMC10337102 | ||
Consent for publication | Not applicable. | PMC10337102 | ||
Competing interest | The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. | PMC10337102 | ||
References | PMC10337102 | |||
Background | death, hypertension, cardiovascular disease | EVENTS, HYPERTENSION, CARDIOVASCULAR DISEASE | Early identification and control of hypertension is critical to reducing cardiovascular disease events and death. U.S. Preventive Services Task Force guidelines recommend health care professionals screen all adults for hypertension, yet 1 in 4 adults with hypertension are unaware of their condition. This gap between gu... | PMC9874175 |
Methods | Study participants were PCPs ( | PMC9874175 | ||
Results | HYPERTENSION | Overall, PCPs preferred and trusted clinic BP measurement for diagnosing hypertension, particularly when measured with a manual sphygmomanometer. Concerns with HBPM included the belief that patients did not follow protocols for rest and body positioning at home, that home machines were not accurate, that home BPs could... | PMC9874175 | |
Conclusions | HYPERTENSION | Our findings suggest that both additional physician education and training and investments in equipment and system-level processes are needed to increase the acceptance and utilization of out of office BP measurement for identification and treatment of hypertension. These changes are needed to improve ensure everyone i... | PMC9874175 | |
Trial registration | ClinicalTrials.gov | PMC9874175 | ||
Supplementary Information | The online version contains supplementary material available at 10.1186/s12875-022-01950-1. | PMC9874175 | ||
Keywords | PMC9874175 | |||
Introduction | disability, death, hypertension, Hypertension | HYPERTENSION, HYPERTENSION | Hypertension is the most common cause of avoidable death and disability globally [Currently, the U.S. Preventive Services Task Force (USPSTF) guidelines recommend screening all adults aged 18 years or older for hypertension (an “A” recommendation, strong evidence of benefit) [These guidelines contrast with current prac... | PMC9874175 |
Methods | PMC9874175 | |||
Goal | hypertension | HYPERTENSION | The goal was to assess primary care physicians’ (PCPs) attitudes and practices after being exposed to a variety of BP measurement options for hypertension diagnosis. (See | PMC9874175 |
Sampling and recruitment | RECRUITMENT | This qualitative study included PCPs (Summary of BP-CHECK measurement methodsThe interviews analyzed for this paper focused on PCPs at Kaiser Permanente Washington who received ABPM results for a BP-CHECK study participant, to ensure they had some experience with this testing methodology. A purposive sampling matrix wa... | PMC9874175 | |
Data collection | SE | Phone interviews took place between March 2018 and April 2019 and were conducted by experienced qualitative researchers (SE and LH) who followed a semi-structured interview guide. Participants provided verbal consent and were offered $50 as thanks for participation. Interviews were recorded and transcribed for analysis... | PMC9874175 | |
Data analysis | SE | Transcripts were coded by three qualitative researchers (SE, LH & CH). Using a template analysis approach [Once coding was complete, data were pulled by code and selected codes were analyzed further. This analysis was summarized in one or more analytic coding memos [ | PMC9874175 | |
Discussion | arrhythmias, hypertension, anxiety | ARRHYTHMIAS, HYPERTENSION, PCP, HBP | Interviews with PCPs who had experience with ABPM through the BP-CHECK randomized trial revealed that overall, they preferred clinic-based BP measurement for hypertension diagnosis, especially manual BP measurement. PCPs viewed measurement in clinics as accurate because it is performed by a trained professional who can... | PMC9874175 |
Conclusion | hypertension | EVENTS, HYPERTENSION, PCP | Ensuring that individuals with hypertension are appropriately identified and treated is critical to preventing cardiovascular events. Current guidelines recommend confirming elevated clinic measurements in individuals without known hypertension through out-of-clinic BP measurements to establish a diagnosis. Our finding... | PMC9874175 |
Acknowledgements | We would like to thank participating PCPs for their willingness to share their views and experiences, Chris Tachibana for her contributions as the scientific editor on this manuscript, and James Licitra for his help with formatting and references. | PMC9874175 | ||
Authors’ contributions | CH: Led the design of data collection processes. Led the analysis of the data. Led the drafting and revision of the manuscript. LH: Participated in the collection of qualitative data. Assisted with data analysis. Reviewed and gave input on drafts of the manuscript. KE: Participated in the design and execution of the da... | PMC9874175 | ||
Funding | This work was supported through a Patient-Centered Outcomes Research Institute (PCORI) Project Program Award (CER-1511–32979). All statements in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of PCORI. | PMC9874175 | ||
Availability of data and materials | The authors declare that the data supporting the findings of this study are available within the article. However, additional data are available upon request from the corresponding author [CH]. The data are not publicly available since they contain information that could compromise research respondents’ confidentially ... | PMC9874175 | ||
Declarations | PMC9874175 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.